Who are SSRI/SNRI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Escitalopram, venlafaxine, Paroxetine + Venlafaxine XR, SSRI/Clomipramine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ssri-snri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SSRI/SNRI — Competitive Intelligence Brief

SSRI/SNRI (SSRI/SNRI) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI/SNRI. Area: Psychiatry/Neurology.

marketed SSRI/SNRI Serotonin transporter (SERT); norepinephrine transporter (NET) for SNRIs Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

SSRI/SNRI (SSRI/SNRI) — UCB Pharma. SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SSRI/SNRI TARGET	SSRI/SNRI	UCB Pharma	marketed	SSRI/SNRI	Serotonin transporter (SERT); norepinephrine transporter (NET) for SNRIs
Escitalopram, venlafaxine	Escitalopram, venlafaxine	K. Lieb	marketed	SSRI/SNRI combination	Serotonin transporter (SERT); norepinephrine transporter (NET)
Paroxetine + Venlafaxine XR	Paroxetine + Venlafaxine XR	Ministry of Health & Welfare, Korea	marketed	SSRI/SNRI combination	Serotonin transporter (SERT), Norepinephrine transporter (NET)
SSRI/Clomipramine	SSRI/Clomipramine	AstraZeneca	phase 3	SSRI/SNRI	Serotonin transporter, Norepinephrine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI/SNRI class)

AstraZeneca · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SSRI/SNRI — Competitive Intelligence Brief. https://druglandscape.com/ci/ssri-snri. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab